
Erasca Inc (ERAS) Stock Forecast & Price Target
Erasca Inc (ERAS) Analyst Ratings
Bulls say
Erasca is a clinical-stage precision oncology company with a pipeline of promising therapies for RAS/MAPK pathway-driven cancers. With two clinical-stage programs and a discovery-stage program, the company has a robust portfolio and potential for blockbuster opportunities in the future. The recent data update and potential for combination therapies with its selective profile make Erasca a strong investment option with potential for growth. Risks to consider include regulatory, commercial, clinical development, manufacturing, financial, liability, and intellectual property.
Bears say
Erasca is a clinical-stage precision oncology company with a focused pipeline targeting RAS/MAPK-driven cancers. Recently, ERAS-0015, a pan-RAS molecular glue, has shown early indications of clinical activity with minimal toxicity and favorable pharmacokinetics, positioning it as a potential best-in-class therapy. However, there are still risks to consider, including regulatory, commercial, and clinical development risks, before the company can fully capitalize on its potential in the market.
This aggregate rating is based on analysts' research of Erasca Inc and is not a guaranteed prediction by Public.com or investment advice.
Erasca Inc (ERAS) Analyst Forecast & Price Prediction
Start investing in Erasca Inc (ERAS)
Order type
Buy in
Order amount
Est. shares
0 shares